Holen Sie sich die Stockscreener-App
10.97
0.27%
0.03
Handel nachbörslich:
11.08
0.11
+1.00%
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India
H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India
Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India
JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus
Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com
Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance
Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks
(ROIV) Trading Advice - news.stocktradersdaily.com
Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
Roivant Sciences Earnings Call: Balancing Growth and Challenges - MSN
Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline - MSN
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript - Insider Monkey
Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday - Insider Monkey
Roivant Sciences Ltd (ROIV) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada
Roivant Sciences Reports Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates - MSN
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm – Company AnnouncementFT.com - Financial Times
ROIV Crosses Above Key Moving Average Level - Nasdaq
Roivant Sciences earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences Q4 2025 Earnings Call Transcript - MarketBeat
Roivant Sciences (ROIV) Stock Jumps Nearly 5%: What’s Fueling This Biotech Rally? - Daily Chhattisgarh News
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Transcript : Roivant Sciences Ltd., Q4 2025 Earnings Call, May 29, 2025 - marketscreener.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024. - marketscreener.com
Roivant Sciences Ltd. Reports Q4 and FY 2025 Financial Results - TradingView
Roivant (ROIV) Reports Decrease in Q4 Revenue but Highlights Strategic Progress | ROIV Stock News - GuruFocus
Roivant Sciences Fiscal Q4 Net Loss Widens, Revenue Falls - marketscreener.com
Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com
Earnings Flash (ROIV) Roivant Sciences Reports Q4 Revenue $7.6M, vs. FactSet Est of $54.1M - marketscreener.com
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update - Yahoo Finance
H.C. Wainwright maintains $18 target on Roivant Sciences stock - Investing.com Australia
Roivant Sciences (NASDAQ:ROIV) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock - MSN
Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com
Roivant Sciences's Earnings Outlook - Nasdaq
What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings - GuruFocus
H.C. Wainwright maintains $18 target on Roivant Sciences stock By Investing.com - Investing.com India
Roivant Sciences (ROIV) Receives Reiterated Buy Rating from HC W - GuruFocus
Ameriprise Financial Inc. Lowers Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com
Roivant Sciences (ROIV) Projected to Post Quarterly Earnings on Thursday - Defense World
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - FinancialContent
Bank of America Corp DE Cuts Stake in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
Don't Ignore The Insider Selling In Roivant Sciences - simplywall.st
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):